MA45684A - Protéine d'apport du cerveau - Google Patents
Protéine d'apport du cerveauInfo
- Publication number
- MA45684A MA45684A MA045684A MA45684A MA45684A MA 45684 A MA45684 A MA 45684A MA 045684 A MA045684 A MA 045684A MA 45684 A MA45684 A MA 45684A MA 45684 A MA45684 A MA 45684A
- Authority
- MA
- Morocco
- Prior art keywords
- supply protein
- brain supply
- brain
- protein
- supply
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70582—CD71
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1651065 | 2016-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45684A true MA45684A (fr) | 2019-05-22 |
Family
ID=59593007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045684A MA45684A (fr) | 2016-07-14 | 2017-07-13 | Protéine d'apport du cerveau |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11498974B2 (fr) |
| EP (1) | EP3484918A1 (fr) |
| JP (2) | JP2019529345A (fr) |
| KR (1) | KR20190039696A (fr) |
| CN (1) | CN109476728A (fr) |
| AU (1) | AU2017297804A1 (fr) |
| BR (1) | BR112019000098A2 (fr) |
| CA (1) | CA3028035A1 (fr) |
| IL (1) | IL263773A (fr) |
| MA (1) | MA45684A (fr) |
| MX (1) | MX2019000529A (fr) |
| PH (1) | PH12018502451A1 (fr) |
| RU (1) | RU2019102746A (fr) |
| SG (2) | SG11201810801QA (fr) |
| WO (1) | WO2018011353A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019016374A2 (pt) | 2017-02-17 | 2020-04-07 | Bristol-Myers Squibb Company | anticorpos para alfa-sinucleína e usos dos mesmos |
| ES2932759T3 (es) | 2017-02-17 | 2023-01-25 | Denali Therapeutics Inc | Polipéptidos de unión al receptor de transferrina diseñados |
| CA3118692A1 (fr) * | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Therapie genique de maladies neurodegeneratives a base de cellules |
| WO2021205358A1 (fr) * | 2020-04-08 | 2021-10-14 | Janssen Biotech, Inc. | Compositions et méthodes d'administration à la barrière hémato-encéphalique |
| US20240141027A1 (en) | 2021-06-11 | 2024-05-02 | Bioarctic Ab | Bispecific binding molecule |
| WO2023128702A1 (fr) * | 2021-12-31 | 2023-07-06 | 주식회사 아임뉴런 | Protéine de fusion perméable à la barrière hémato-encéphalique et ses utilisations |
| CN119137153A (zh) * | 2022-05-05 | 2024-12-13 | 伊莱利利公司 | 多特异性结合分子及其使用方法 |
| WO2024080843A1 (fr) * | 2022-10-14 | 2024-04-18 | 주식회사 아임뉴런 | Protéine de fusion perméable à la barrière hémato-encéphalique et son utilisation |
| IL321347A (en) * | 2022-12-08 | 2025-08-01 | Adel Inc | Fusion comprising anti-tau antibody and peptide and use thereof |
| KR20250162888A (ko) | 2023-03-24 | 2025-11-19 | 바이오악틱 에이비 | 인간 트랜스페린 수용체 htfr1의 프로테아제-유사 도메인에 결합하는 이중특이적 항체 |
| WO2024263567A2 (fr) * | 2023-06-21 | 2024-12-26 | Eli Lilly And Company | Composés pour l'administration de granuline à travers la barrière hémato-encéphalique |
| WO2025007703A1 (fr) * | 2023-07-04 | 2025-01-09 | Beijing Neox Biotech Limited | Anticorps anti-tfr1 et leurs utilisations |
| US20250388664A1 (en) | 2024-06-20 | 2025-12-25 | Bioarctic Ab | Bispecific binding molecule |
| US20260035475A1 (en) | 2024-06-20 | 2026-02-05 | Bioarctic Ab | Stabilized binding molecule |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| PL2004688T5 (pl) | 2006-03-23 | 2014-09-30 | Bioarctic Neuroscience Ab | Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania |
| US8497246B2 (en) * | 2006-08-18 | 2013-07-30 | Armagen Technologies, Inc. | Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions |
| CN104116736A (zh) | 2008-04-24 | 2014-10-29 | 百时美施贵宝公司 | 埃坡霉素D在治疗包括阿尔茨海默病的τ相关疾病中的用途 |
| JP5747414B2 (ja) | 2008-04-29 | 2015-07-15 | バイオアークティック ニューロサイエンス アーベー | α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン |
| US8697074B2 (en) | 2008-07-10 | 2014-04-15 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods and compositions for enhanced delivery of macromolecules |
| PL2448968T3 (pl) | 2009-06-29 | 2021-09-13 | Bioarctic Ab | Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta |
| NO2539366T3 (fr) | 2010-02-26 | 2018-04-07 | ||
| JP6050747B2 (ja) * | 2010-06-17 | 2016-12-21 | トレリス バイオサイエンス リミテッド ライアビリティー カンパニー | インフルエンザ受動免疫化に有用な抗体 |
| CN110251668A (zh) | 2010-11-30 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | 低亲和力血脑屏障受体抗体及其用途 |
| KR20190121874A (ko) * | 2012-08-29 | 2019-10-28 | 에프. 호프만-라 로슈 아게 | 혈액 뇌 장벽 셔틀 |
| US9475874B2 (en) * | 2013-08-26 | 2016-10-25 | MabVax Therapeutics, Inc. | Nucleic acids encoding human antibodies to sialyl-lewisa |
| CA2944402A1 (fr) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Navettes de la barriere hemato-encephalique contenant des anticorps reconnaissant l'alpha-synucleine |
| SMT202100263T1 (it) * | 2014-07-10 | 2021-07-12 | Eisai R&D Man Co Ltd | Anticorpi leganti protofibrille a-beta migliorati |
-
2017
- 2017-07-13 MA MA045684A patent/MA45684A/fr unknown
- 2017-07-13 SG SG11201810801QA patent/SG11201810801QA/en unknown
- 2017-07-13 EP EP17751619.2A patent/EP3484918A1/fr not_active Withdrawn
- 2017-07-13 RU RU2019102746A patent/RU2019102746A/ru not_active Application Discontinuation
- 2017-07-13 WO PCT/EP2017/067727 patent/WO2018011353A1/fr not_active Ceased
- 2017-07-13 JP JP2019501707A patent/JP2019529345A/ja active Pending
- 2017-07-13 CN CN201780042832.1A patent/CN109476728A/zh active Pending
- 2017-07-13 AU AU2017297804A patent/AU2017297804A1/en not_active Abandoned
- 2017-07-13 KR KR1020197002785A patent/KR20190039696A/ko not_active Ceased
- 2017-07-13 MX MX2019000529A patent/MX2019000529A/es unknown
- 2017-07-13 BR BR112019000098-4A patent/BR112019000098A2/pt not_active Application Discontinuation
- 2017-07-13 SG SG10201912842VA patent/SG10201912842VA/en unknown
- 2017-07-13 US US16/317,156 patent/US11498974B2/en active Active
- 2017-07-13 CA CA3028035A patent/CA3028035A1/fr not_active Abandoned
-
2018
- 2018-11-21 PH PH12018502451A patent/PH12018502451A1/en unknown
- 2018-12-17 IL IL263773A patent/IL263773A/en unknown
-
2022
- 2022-06-30 JP JP2022106495A patent/JP7589194B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201810801QA (en) | 2019-01-30 |
| JP2019529345A (ja) | 2019-10-17 |
| BR112019000098A2 (pt) | 2019-04-09 |
| PH12018502451A1 (en) | 2019-09-30 |
| US20190225699A1 (en) | 2019-07-25 |
| EP3484918A1 (fr) | 2019-05-22 |
| SG10201912842VA (en) | 2020-02-27 |
| WO2018011353A1 (fr) | 2018-01-18 |
| US11498974B2 (en) | 2022-11-15 |
| RU2019102746A3 (fr) | 2020-11-30 |
| JP7589194B2 (ja) | 2024-11-25 |
| KR20190039696A (ko) | 2019-04-15 |
| AU2017297804A1 (en) | 2019-01-24 |
| JP2022130646A (ja) | 2022-09-06 |
| RU2019102746A (ru) | 2020-08-14 |
| CN109476728A (zh) | 2019-03-15 |
| CA3028035A1 (fr) | 2018-01-18 |
| MX2019000529A (es) | 2020-01-15 |
| IL263773A (en) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45684A (fr) | Protéine d'apport du cerveau | |
| EP3430731A4 (fr) | Architecture d'iugw | |
| EP3463146A4 (fr) | Ensembles chirurgicaux robotiques | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| KR20180085041A (ko) | 칫솔 | |
| EP3547968A4 (fr) | Prothèse obtenu par génie tissulaire | |
| EP3518708A4 (fr) | Structure d'assise souple | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| HRP20190412T1 (hr) | Konstrukti proteina uspa2 i njihova upotreba | |
| EP3437540A4 (fr) | Support d'endoscope | |
| DK3145946T3 (da) | Bakteriebaseret proteintilførsel | |
| MA50174A (fr) | Formules de protéines de fusion vegfr-fc | |
| EP3487471A4 (fr) | Tétine artificielle de protection contre les morsures | |
| HUE064240T2 (hu) | Fehérjetisztítás | |
| IL260347A (en) | Therapeutic anti-cd9 antibody | |
| MA43873A (fr) | Dspositif d'injection | |
| DK3737402T5 (da) | Modificeret protein | |
| EP3583844A4 (fr) | Système d'aquaculture | |
| EP3512771A4 (fr) | Siège d'aéronef | |
| EP3525479A4 (fr) | Casque d'écoute | |
| EP3431808A4 (fr) | Butée d'arrêt | |
| EP3445974A4 (fr) | Réchauffeur d'air | |
| EP3444345A4 (fr) | Dérivé d'arnmicro-143 | |
| ZA201902689B (en) | Therapeutic protein | |
| EP3343013A4 (fr) | Collecteur d'admission |